A US health advisory panel narrowly voted to recommend easing restrictions on injectable peptides like BPC-157, despite FDA scientists' concerns about their unproven safety and efficacy. The recommendation, if followed by the FDA, could make these substances more widely available via prescription.
The panel's recommendation could lead to increased availability of peptides for consumers, potentially impacting the wellness and pharmaceutical industries, while raising public health concerns due to unproven safety and efficacy.
A US Food and Drug Administration (FDA) advisory panel has narrowly recommended easing restrictions on controversial peptides, including BPC-157, TB-500, and KPV, which have gained popularity online despite limited research for human use. The panel voted 8-6, with one abstention, to allow specialized pharmacies to produce these substances, a significant step toward making them available via prescription. FDA scientists have voiced concerns about the lack of clinical data proving the safety and efficacy of these peptides. The panel's recommendation is advisory, and the FDA is not obligated to follow it, though it often does. Health Secretary Robert F Kennedy Jr has previously expressed support for peptides and sought to reduce restrictions. Some panel members with industry ties voted in favor, citing "the greater good" and "medical freedom," while others expressed concerns about market-driven demand overriding scientific evidence. Medical experts caution that the current peptide market is largely unregulated.
Pick the topics you care about. Get only what matters, on your cadence.